Metastatic Solid Tumors.
Conditions
Brief summary
This is a phase II, multi-center (Israeli), open label, non-randomized trial for every patient with the specified tumors expressing c-kit or PDGFR. Expression of these kinases will be investigated in tumor samples obtained at the time of diagnosis or from the time of recurrent disease. Every patient with positive expression of either of the kinases will be evaluated for quantitative and qualitative evidence of disease prior to entry into the study, and if possible, no other treatment will be given concomitantly, to allow evaluation of the net effect of Glivec on tumor growth kinetics, searching for measurable evidence of response. Glivec is supplied to the study investigators by Novartis Pharmaceutical. Patients will receive Glivec 400mg-800mg p.o./day for an exposure period of up to 12 months provided that in the opinion of the investigator the patient is benefiting from treatment with Glivec, and in the absence of any safety concern. For patients with brain tumors who are not receiving concomitant enzyme inducing anti-convulsant drugs, the recommended dose of Glivec is 800mg/day.
Interventions
DRUGGlivec
Sponsors
Novartis
Hadassah Medical Organization
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients \> 18 years of age. * Histologically documented diagnosis of one of the specified tumors, which is malignant as well as unresectable and/or metastatic and therefore, incurable with any conventional multimodality approach and immunohistochemical documentation of c-kit (CD117) or PDGFR expression in the primary tumor or metastases by tumor (preferably on a tumor sample taken within 6 week of study entry). * At least one measurable site of disease as defined by Southwestern Oncology Group Solid Tumor Response Criteria. * Female patients of child-bearing potential must have negative pregnancy test. * Signed informed consent form. * Life expectancy \>3 months.
Exclusion criteria
* Patient has received any other investigational agents within 28 days of the first day of study drug dosing. * Existence of any evidence of another malignant disease, except superficial non-melanoma skin cancer. * Patient has a known brain metastases. * Patient previously received radiotherapy to \>25% of the bone marrow.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate activity of Glivec in escalating doses 400 up to 800mg/day in patients with a large variety of metastatic solid tumors expressing c-kit or PDGFR. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate the toxicity of Glivec in patients with solid tumors. | — |
Countries
Israel
Outcome results
None listed